Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.35 |
| ▸ | DRD2 | P14416 | 10/20 | 0.35 |
| ▸ | P4HB | P07237 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433179 | 0.82 | HTR1A (0.35) | DRD2P4HBDRD1SMAD3 | |
| SCHEMBL2429034 | 0.80 | DRD1 (0.39) | DRD2P4HBDRD1 | |
| SCHEMBL2429837 | 0.70 | SCN9A (0.35) | — | |
| SCHEMBL2431166 | 0.66 | P4HB (0.31) | P4HB | |
| SCHEMBL2431152 | 0.65 | SCN9A (0.44) | — | |
| SCHEMBL2994860 | 0.64 | SCN9A (0.52) | — | |
| SCHEMBL281983 | 0.63 | ALDH1A1 (0.40) | — | |
| SCHEMBL281099 | 0.63 | P4HB (0.47) | P4HBSMAD3 | |
| SCHEMBL281812 | 0.62 | SCN9A (0.53) | HTR2ADRD2 | |
| SCHEMBL27707819 | 0.62 | SCN9A (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | HTR2A 557/4885HTR2C 643/4885DRD2 590/4885 |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | HTR2A 557/4885HTR2C 643/4885DRD2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.